

Guidelines International Network Standards for Clinical Practice Guidelines

Title of the Guideline	Newer Pharmacologic Treatments in Adults with Type 2 Diabetes: A Clinical Guideline From the American College of Physicians
Name of the Developing Organisation	American College of Physicians
Publication Date	April 19, 2024

Effective August 2013, G-I-N is requesting voluntary reporting on the G-I-N Guideline Standards¹ when a guideline is submitted for inclusion in the G-I-N Library.

Is your organisation willing to complete the form to provide information to a reader about your guideline?

YES ☒

NO ☐

If Yes, please complete the checklist on the next page.

G-I-N Standards & Description¹	Standard Achieved?	If Yes, Page number(s)/document where the information is available
<u>Composition of Guideline Development Group</u> Guideline development panel includes diverse and relevant stakeholders, such as health professionals, methodologists, experts on a topic, and patients.	X YES <input type="checkbox"/> NO <input type="checkbox"/> Somewhat	See <i>Appendix: Panel Composition and Stakeholder Involvement</i> . See ACP guidelines and guidance statements methods paper (citation under additional comments)
<u>Decision-making Process</u> Guideline describes the process used to reach consensus among the panel members and, if applicable, approval by the sponsoring organisation. This process was established before the start of guideline development.	X YES <input type="checkbox"/> NO <input type="checkbox"/> Somewhat	See ACP guidelines and guidance statements methods paper (citation under additional comments)
<u>Conflicts of Interest (disclosure)</u> Guideline includes disclosure of the financial and nonfinancial conflicts of interest for members of the guideline development group.	X YES <input type="checkbox"/> NO <input type="checkbox"/> Somewhat	See <i>Disclosures</i> in article, author, & disclosure information See ACP disclosures of interests and management of conflicts of interest methods paper (citation under additional comments)
<u>Conflicts of Interest (resolution)</u> Guideline describes how any identified conflicts were recorded and resolved.	X YES <input type="checkbox"/> NO <input type="checkbox"/> Somewhat	See <i>Disclosures</i> in article, author, & disclosure information See ACP disclosures of interests and management of conflicts of interest

		methods paper (citation under additional comments)
G-I-N Standards & Description¹	Standard Achieved?	If Yes, page number(s)/document where the information is available
<u>Scope of a Guideline</u> Guideline specifies its objective(s) and scope.	X YES <input type="checkbox"/> NO <input type="checkbox"/> Somewhat	See <i>Scope and Purpose</i> section
<u>Methods</u> Guideline clearly describes the methods used for the guideline development in detail.	X YES <input type="checkbox"/> NO <input type="checkbox"/> Somewhat	See <i>Guideline Development Process</i> section See <i>Appendix: Additional Details of Guideline Methods</i> See ACP guidelines and guidance statements methods paper (citation under additional comments)
<u>Evidence Reviews</u> Guideline uses systematic evidence review methods to identify and evaluate evidence related to the guideline topic.	X YES <input type="checkbox"/> NO <input type="checkbox"/> Somewhat	See <i>Systematic Review of Benefits and Harms and Summary of the Evidence</i> section See <i>Appendix: Systematic Review</i>
<u>Guideline Recommendations</u> Guideline recommendation clearly stated and based on scientific evidence of benefits; harms; and, if possible, costs.	X YES <input type="checkbox"/> NO <input type="checkbox"/> Somewhat	See <i>Recommendations</i> section for rationale following each recommendation statement. See evidence-to-

		<p>decision framework (Supplement)</p> <p>See ACP guidelines and guidance statements methods paper (citation #20 under References section)</p>
<p><u>Rating of Evidence</u></p> <p>Guideline uses a rating system to communicate the quality and reliability of the evidence.</p>	<p>X YES</p> <p><input type="checkbox"/> NO</p> <p><input type="checkbox"/> Somewhat</p>	<p>See <i>Guideline Development Process</i> section and Figure 1</p> <p>See evidence-to-decision framework (Supplement)</p> <p>See ACP guidelines and guidance statements methods paper (citation under additional comments)</p>
G-I-N Standards & Description¹	Standard Achieved?	If Yes, page number(s)/document where the information is available
<p><u>Rating of Recommendations</u></p> <p>Guideline uses a rating system to communicate the quality and reliability of the strength of its recommendations.</p>	<p>X YES</p> <p><input type="checkbox"/> NO</p> <p><input type="checkbox"/> Somewhat</p>	<p>See Figure 1 and <i>Recommendations</i> section</p> <p>See Appendix Table 2</p> <p>See ACP guidelines and guidance statements methods paper (citation under additional comments)</p>
<p><u>Peer Review and Stakeholder Consultations</u></p> <p>Review by external stakeholders conducted before guideline publication.</p>	<p>X YES</p> <p><input type="checkbox"/> NO</p> <p><input type="checkbox"/> Somewhat</p>	<p>See <i>Appendix: Peer Review</i></p>

<u>Guideline Expiration and Updating</u> Guideline includes an expiry date and/or describes the process that the guideline groups will use to update recommendations.	X YES <input type="checkbox"/> NO <input type="checkbox"/> Somewhat	See Appendix: <i>Guideline Expiration or Living Guideline Process</i>
<u>Financial Support and Sponsoring Organisation</u> Guideline discloses financial support for the development of both the evidence review as well as the guideline recommendations.	X YES <input type="checkbox"/> NO <input type="checkbox"/> Somewhat	See <i>Financial Support</i> in article, author, & disclosure information

Additional Comments

Guideline:

- Qaseem A, Obley AJ, Shamliyan T, et al. Newer pharmacologic treatments in adults with type 2 diabetes: a clinical guideline from the American College of Physicians. *Ann Intern Med.* 19 April 2024. [Epub ahead of print]. doi:10.7326/M23-2788
- Visual Guideline - Newer pharmacologic treatments in adults with type 2 diabetes: a visual clinical guideline from the American College of Physicians. *Ann Intern Med.* Epub 2024 April 19. doi:10.7326/M24-0803

Supporting Evidence Reviews:

- Drake T, Landsteiner A, Langsetmo L, et al. Newer pharmacologic treatments in adults with type 2 diabetes: a systematic review and network meta-analysis for the American College of Physicians. *Ann Intern Med.* 19 April 2024. [Epub ahead of print]. doi:10.7326/M23-1490
- Schousboe JT, Landsteiner A, Drake T, et al. Cost-effectiveness of newer pharmacologic treatments in adults with type 2 diabetes: a systematic review of cost-effectiveness studies for a clinical guideline of the American College of Physicians. *Ann Intern Med.* 19 April 2024. [Epub ahead of print]. doi:10.7326/M23-1492

Methods papers:

Qaseem A, Kansagara D, Lin JS, et al, for the Clinical Guidelines Committee of the American College of Physicians. [The Development of Clinical Guidelines and Guidance Statements by the Clinical Guidelines Committee of the American College of Physicians: Update of Methods](#). *Ann*

Intern Med. 2019; 170:863–870. [Epub ahead of print 11 June 2019]. [PMID: 31181568]. doi: 10.7326/M18-3290

Qaseem A, Wilt TJ, for the Clinical Guidelines Committee of the American College of Physicians. [Disclosure of Interests and Management of Conflicts of Interest in Clinical Guidelines and Guidance Statements: Methods From the Clinical Guidelines Committee of the American College of Physicians](#). Ann Intern Med. 2019; 171:354–361. [Epub ahead of print 20 August 2019]. doi: 10.7326/M18-3279